Nebenwirkungen · Duloxetine Lilly
Duloxetine Lilly 30 mg hard gastro-resistant capsules Duloxetine Lilly 60 mg hard gastro-resistant capsules · Abschnitt 4.8 · PDF-Seite 12
HOS-133608 · Präparat HOS-097464
1 Cases of convulsion and cases of tinnitus have also been reported after treatment discontinuation. 2 Cases of orthostatic hypotension and syncope have been reported especially at the initiation of treatment. 3 See section 4.4. 4 Cases of aggression and anger have been reported particularly early in treatment or after treatment discontinuation. 5 Cases of suicidal ideation and suicidal behaviours have been reported during duloxetine therapy or early after treatment discontinuation (see section 4.4). 6 Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in placebo-controlled clinical trials. 7 Not statistically significantly different from placebo. 8 Falls were more common in the elderly (≥65 years old). 9 Estimated frequency based on all clinical trial data. 10 Estimated frequency based on placebo-controlled clinical trials.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 61054d41822a6a0df108fca29fbebcc411cb952e97947b2c207af5bcdba0577a · Passage 7e75c15c19a993e02463c16b21dac87966df607cc221d86231076ce2d8918490 · Zeichen 7830–8747 im Abschnitt